() Cohort III-2 99,619 Aim: To evaluate and benefits of Second-line cfDNA screening under current The study study different scenarios for second-line cfDNA screening conditions would maintain today's assumed that screening. 7.90/000 live birth prevalence of Down cfDNA testing syndrome (LBPD) at an 11% reduction of has a sensitivity Setting: Belgium overall short-term costs. Lowering the of 99.3% and a Population: Pregnancies screened by screening threshold to 1:600 or increasing specificity of combined first trimester screening (78.5%) or sensitivity by 10% would reduce LBPD to 99.84% for second trimester screening (21.5%) in 2011 70/000 at a maximum 3% increase of overall trisomy 21 () Methods: Data from the Belgian National short-term costs. Institute for Health and Disability Insurance Rates of procedure-related miscarriage and the Study Centre for Perinatal were lower with cfDNA than with current Epidemiology were used in modeled screening (0.03 vs 0.06%) with a risk threshold calculations of medical and economic of 1:300 or 1:600. impact of cfDNA testing after prior conventional screening (1) at thresholds 1:300 and 1:600, and (2) at current and improved screening sensitivity. Outcomes: Detection of trisomy 21, rate of procedure-related miscarriage, costs
() Cohort study III-2 99,619 Aim: To evaluate and benefits of different scenarios for second-line cfDNA screening. Setting: Belgium Population: Pregnancies screened by combined first trimester screening (78.5%) or second trimester screening (21.5%) in 2011 Methods: Data from the Belgian National Institute for Health and Disability Insurance and the Study Centre for Perinatal Epidemiology were used in modeled calculations of medical and economic impact of cfDNA testing after prior conventional screening (1) at thresholds 1:300 and 1:600, and (2) at current and improved screening sensitivity. Outcomes: Detection of trisomy 21, rate of procedure-related miscarriage, costs Second-line cfDNA screening under current screening conditions would maintain today's 7.90/000 live birth prevalence of Down syndrome (LBPD) at an 11% reduction of overall short-term costs. Lowering the screening threshold to 1:600 or increasing sensitivity by 10% would reduce LBPD to 70/000 at a maximum 3% increase of overall short-term costs. Rates of procedure-related miscarriage were lower with cfDNA than with current screening (0.03 vs 0.06%) with a risk threshold of 1:300 or 1:600. The study assumed that cfDNA testing has a sensitivity of 99.3% and a specificity of 99.84% for trisomy 21 ()
cfDNA%20testing%20evidence%20evaluation%2016May17.docx